CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026

Stock Information for Cytodyn Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cytodyn Inc

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
Life Sciences Virtual Investor Forum Agenda Announced
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
Kessler Topaz Meltzer & Check, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of CytoDyn Inc. common stock
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.